FINWIRES · TerminalLIVE
FINWIRES

ASMPT Issues 1.6 Million Shares Under Employee Incentive Scheme

By

ASMPT (HKG:0522) allotted and issued 1.6 million new shares under its employee share incentive scheme, according to a Monday Hong Kong bourse filing.

Shares of the chip gear maker were down nearly 2% in Tuesday morning trade.

The awarded shares were subscribed for in cash by the scheme trustee and will be transferred to selected employees subject to vesting conditions.

The new shares represent about 0.4% of ASMPT's existing issued share capital and were issued at a par value of HK$0.10 each.

ASMPT expects to raise HK$157,125 from the share issue for general working capital purposes.

Related Articles

Asia

Shandong Yisheng Livestock & Poultry Breeding's Broiler Chick, Pig Sales Rise in April

Shandong Yisheng Livestock & Poultry Breeding's (SHE:002458) broiler chick sales revenue jumped 55% to 219 million yuan in April, according to a Tuesday filing with the Shenzhen bourse.Sales volume grew 13 to 55.3 million broiler chicks.Its Yisheng 909 mini broiler chicks saw sales revenue of 12.8 million yuan, up 104% year over year, while its sales volume jumped 19% to 8.2 million.Breeding pig sales revenue surged 325% to 40.4 million yuan while sales volume expanded 478% to 19,521 breeding pigs.

$SHE:002458
Asia

Trendlines, Controlling Shareholder to Invest Combined $1.4 Million in Portfolio Firms

Trendlines Group (SGX:42T) said its board approved a capital injection into portfolio companies Ceretrieve and Vensica Medical by controlling shareholder Librae Holdings.Shares of the agrifood and med-tech company were down over 1% in Tuesday's afternoon trade.Librae will invest around $850,000 in the units. Additionally, Trendlines will infuse a total of $550,000 to the portfolio firms, according to a Monday filing with the Singapore Exchange.The funding is aimed at supporting the ongoing operations of the portfolio companies and helping them achieve successful exits, the filing said.Ceretrieve develops neurointerventional devices, while Vensica Medical specializes in bladder-targeted therapies.

$SGX:42T
Asia

Galaxy Entertainment Revenue Rises 11% in Q1 2026

Galaxy Entertainment Group (HKG:0027) reported HK$12.4 billion in first quarter 2026 revenue, up 11% from HK$11.20 billion a year earlier, according to a Tuesday filing with the Hong Kong bourse.Revenue from the gaming business increased to HK$10.02 billion from HK$8.92 billion in the prior year. Non-gaming revenue stood at HK$1.71 billion, rising from HK$1.56 billion, while sales from construction materials fell to HK$666 million from HK$723 million, figures showed.

$HKG:0027